Akeso, Inc. is a biopharmaceutical company engaged in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on major disease areas including oncology, autoimmune diseases, respiratory diseases, central nervous system disorders, inflammation, and metabolic diseases. Its core technology platform centers on bispecific and multispecific antibodies, antibody-drug conjugates (ADCs), T-cell engagers (TCEs), siRNA, cell therapy, and mRNA. Key commercialized products include cadonilimab, a PD-1/CTLA-4 bispecific antibody, and ivosideb, a PD-1/VEGF bispecific antibody. The company also markets inutuximab, ifosideb, and gumosideb for non-oncology indications. Akeso operates through subsidiaries such as CTTQ-Akeso and Akeso Biopharma, and maintains a joint venture with Chia Tai Tianqing for the exclusive sales and contract manufacturing of its monoclonal antibody products in the PRC. The company has licensed overseas rights for ivosideb to Summit Therapeutics and has received FDA approval for penpulimab for nasopharyngeal carcinoma. Akeso was founded in 2012 and listed on the main board of the Stock Exchange of Hong Kong in 2020.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Biotechnology Homepage akesobio.com
Sector Healthcare IR page akesobio.com/cn/investor-relations/financial-reports
Tags
bispecific antibodies, oncology, antibody-drug conjugates, t-cell engagers, sirna, cell therapy, mrna, autoimmune diseases, respiratory diseases, central nervous system, metabolic diseases, pd-1/ctla-4, cadonilimab, ivosideb, inutuximab, ifosideb, gumosideb, penpulimab, CTTQ-Akeso, Akeso Biopharma, Chia Tai Tianqing, LYG Tianqing, Nanjing Tianqing, Summit Therapeutics, ACE Platform
Press page —

Metrics

Valuation  
Market cap HK$ 57.4B
Market cap (USD) $ 7.315B
P/E -50.43
PEG —
P/BV 5.60
P/S 14.13
P/OCF -113.46
P/FCF —
Dividend yield —
Turnover / mcap 1.1%
Returns  
ROE -14.2%
ROI -11.7%
ROIC -11.7%
Profit margin -36.4%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 11.7%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score -68.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue 3.056B 2.124B 4.526B 837.656M 225.626M 0 70.879M
Net profit -1.113B -514.515M 2.028B -1.168B -1.075B -1.177B -335.386M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 134.35 67.77 36.5 40.32 16.19 20.97 —
Price performance 12m 1.03 0.87 -0.15 1.37 -0.17 — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Akeso, Inc. (ticker 9926), listed in Hong Kong.

ETFs Holding Akeso, Inc.

ETF Weight in ETF Shares Market value As of
MEMA 0.46% 5,000 $ 57.339K Aug 31, 2026
TMED 0.39% 8,000 $ 90.078K Jun 30, 2026
DFSE 0.05% 27,000 $ 294.793K Nov 12, 2026
DFEM 0.03% 242,000 $ 2.642M Nov 12, 2026
DFAE 0.03% 233,000 $ 2.544M Nov 12, 2026
DFAX 0.01% 160,000 $ 1.747M Nov 12, 2026
AVEM 0.01% 456,000 $ 3.683M Nov 16, 2026
JSTC 0.01% 3,970 $ 32.435K Nov 17, 2026